Digoxin degradation in acidic dissolution medium.
The release of digoxin and its simultaneous conversion to digoxigenin bisdigitoxoside, digoxigenin monodigitoxoside, and digoxigenin in a USP dissolution test medium were followed by high-pressure liquid chromatography. Two products, Tablets A and B, were manufactured by solvent deposition and simple blending methods, respectively. Tablet A released digoxin faster than Tablet B in distilled water and in artificial intestinal juice, and no decomposition was observed. In the USP dissolution test medium, the rate of hydrolysis to digoxigenin bisdigitoxoside was almost equal to that of hydrolysis to digoxigenin monodigitoxoside, and a comparatively large formation rate of digoxigenin was observed. Concentrations of digoxin and its decomposition products were described by differential equations that included dissolution rates of digoxin (rapidly dissolving digoxin and digoxin crystals) and an apparent hydrolysis rate. In the earlier stage of dissolution, hydrolysis was rate determining; in the later stage, dissolution became the rate-determining step for overall digoxin degradation. To suppress digoxin hydrolysis in the USP dissolution test medium, a developmental formulation study was performed. The incorporation of magnesium oxide and magnesium hydroxide-aluminum hydroxide in the tablet formulations inhibited digoxin hydrolysis by 15.3 and 14.5%, respectively, after dissolution for 30 min without serious delay of drug release.
D000143:Acids; D000863:Antacids / Q000378:metabolism; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D004071:Digitalis Glycosides / Q000032:analysis; D004076:Digoxigenin / Q000032:analysis; D004077:Digoxin / Q000032:analysis / Q000378:metabolism; D004347:Drug Interactions; D004355:Drug Stability; D006868:Hydrolysis; D007700:Kinetics; D012995:Solubility
D000143:Acids; D000863:Antacids; D004071:Digitalis Glycosides; D004077:Digoxin; D004076:Digoxigenin